Opinion|Videos|May 5, 2025
Comprehensive Molecular Testing in Patients With Ovarian Cancer
Author(s)Bradley J. Monk, MD, FACS, FACOG
A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a timely manner for patients with ovarian cancer, emphasizing the need for better education of health care providers and more affordable, widely available testing options.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Challenges in Comprehensive Molecular Testing
Two primary barriers impact comprehensive molecular testing implementation:
Education:
- Physicians need better awareness about which tests to order, when to order them, and how to interpret results.
- All patients with advanced or recurrent disease should receive comprehensive testing (DNA, RNA, and protein analysis).
- Education must extend to health care providers, patients, and the broader community.
Cost and reimbursement:
- Medicare covers several biomarker tests with little to no patient cost.
- Reimbursement varies by insurance type, with inconsistencies in federal and state funding.
- Improving value requires both better education and more affordable testing options.
Addressing these barriers would support wider adoption of comprehensive molecular testing in ovarian cancer.
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Medicare GLP-1 Bridge Launches, but Who Actually Qualifies?
2
FDA Advisory Committee Supports Moderna mRNA Flu Vaccine Review
3
Online GLP-1 Sellers Often Skip Clinician Oversight
4
Early Treatment Succeeds in CRC With Next-Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo
5